Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
高盛以買入評級啓動對Mineralys Therapeutics的報道,宣佈目標股價爲30美元
Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.
高盛分析師理查德·勞開始對Mineralys Therapeutics(納斯達克股票代碼:MLYS)進行報道,評級爲買入,並宣佈目標股價爲30美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。